Low testosterone isn’t a vanity problem. It’s a whole-body one.

Most men meet testosterone as a punchline — a supplement aisle, a billboard, someone at the gym. That framing has cost a generation of men a serious conversation about a hormone that acts on nearly every tissue they own. Here is what the evidence actually supports, what it does not, and why the monitoring matters more than the molecule.

It was never really about libido

Androgen receptors are not confined to anywhere convenient. They sit in skeletal muscle, in bone, in bone marrow, in fat tissue, in the vascular wall, and throughout the central nervous system. Testosterone is a signal that reaches most of the body, which is why a low level rarely presents as one tidy symptom.

It presents as a man in his early fifties who is flat by two in the afternoon, who trains the same way he did at forty and gets less for it, whose sleep no longer restores anything, and whose annual physical came back with a shrug. Each item on its own is explainable by age or stress. Together, they are a pattern worth measuring.

The decline is real — and it is not uniform

Two of the best long-running cohorts in the field, the Baltimore Longitudinal Study of Aging and the Massachusetts Male Aging Study, put the fall in total testosterone at roughly one to two percent per year from somewhere in the fourth decade. That range is not sloppiness; the figure differs depending on which fraction you measure and whether you follow the same men over time or compare men of different ages.

The more useful detail is buried underneath it. Sex hormone-binding globulin rises about 1.6 percent a year as men age, and SHBG binds testosterone tightly. So the fraction that is actually available to tissue falls roughly twice as fast as the total. This is precisely how a man is told his testosterone is “normal for his age” on a single total measurement while his free level tells a different story — and it is why a proper panel measures total testosterone, free testosterone and SHBG together rather than one number in isolation.

Low testosterone travels in bad company

In observational research, low testosterone sits alongside a long list of things no one wants: reduced muscle mass and strength, lower bone density, insulin resistance and type 2 diabetes, metabolic syndrome, anemia, low mood, and — at the lower end of the range — higher all-cause and cardiovascular mortality.

Now the sentence most clinics leave out. Association is not causation, and low testosterone is substantially a marker of poor health as well as a possible cause of it. Obesity, sleep apnea, heavy alcohol use, opioid and steroid prescriptions, thyroid disease and chronic illness all lower testosterone. In a meaningful number of men, the low number is the smoke rather than the fire — and treating the fire raises the number without a prescription.

That is not an argument against treatment. It is an argument for a diagnosis before one, which is a different thing entirely, and it is the step most often skipped.

The decade of fear, and how it ended

Between 2013 and 2015 a small number of observational studies suggested testosterone therapy might raise cardiovascular risk. The FDA added class-wide cautionary language, prescriptions fell, and a great many men who would have benefited were quietly steered away. The methodology of those studies was contested almost immediately, but the doubt stuck, because doubt does.

The question was settled properly in 2023. TRAVERSE randomized 5,246 men aged 45 to 80 — all with symptoms and two confirmed low morning testosterone measurements, and all with existing cardiovascular disease or high cardiovascular risk. In other words, the exact population you would worry about most. Over a mean follow-up of about 33 months, major adverse cardiac events occurred in 7.0 percent of men on testosterone and 7.3 percent on placebo.

On the strength of that result, the FDA issued class-wide labeling changes on February 28, 2025, removing the boxed-warning language about increased cardiovascular risk from every testosterone product. In June 2026 the agency went further and asked manufacturers to remove the limitation stating that safety and effectiveness had not been established in men with age-related low testosterone, and to narrow the prostate cancer contraindication to metastatic disease only.

Two points of precision, because they are the kind of thing that gets blurred in marketing. That June 2026 change is a request to manufacturers, not a finished rule — and removing a limitation is not the same as adding an approved indication. As things stand, no testosterone product is FDA-approved for men who simply have a low level with no associated medical condition. Prescribing in that situation is a considered clinical judgment, and it should be presented as one.

What the trials did not show

This is the section that tells you whether a clinic is worth trusting.

The Testosterone Trials, run in men over 65, are usually cited as a success. They were, in part: sexual function improved clearly, and anemia improved. But the physical-function trial did not meet its own primary endpoint. Neither did the vitality trial. The cognition trial was flatly null — testosterone did not improve memory or executive function. Bone density and estimated bone strength improved substantially, and yet there were six fractures in each arm.

TRAVERSE, for its part, showed non-inferiority on cardiac events — not benefit. And it surfaced four signals that deserve to be stated rather than buried: more atrial fibrillation (3.5 versus 2.4 percent), more pulmonary embolism (0.9 versus 0.5 percent), more acute kidney injury (2.3 versus 1.5 percent), and more fractures, not fewer. Over eighty percent of those fractures were trauma-related, mostly falls.

So: testosterone therapy is not a heart drug, not a bone drug, not a memory drug, and not a longevity drug. What it reliably does is restore a hormone to a physiologic level in men who are genuinely deficient, and that produces real, well-documented improvements in energy, body composition, sexual function and — in our experience and in the literature — the general sense of operating at your own baseline again. That is a good enough reason. It does not need embellishing.

The prostate, and a quieter reversal

For fifty years the assumption was that testosterone fed prostate cancer. The evidence has not held that up. A collaborative analysis of eighteen prospective studies — nearly 3,900 cases — found no association between circulating testosterone and prostate cancer risk. TRAVERSE, which followed its participants for prostate events, found no significant difference in prostate cancer between groups.

The American Urological Association now advises clinicians to inform patients of the “absence of evidence linking testosterone therapy to the development of prostate cancer.” That is a careful phrase and we will use it carefully: absence of evidence of harm is not proof of safety. TRAVERSE excluded men with a PSA above 3.0 and recorded only a handful of high-grade events, so it says very little about higher-risk men. PSA still gets drawn before therapy in men over 40, and it still gets rechecked.

The part that makes it work is the part nobody sees

Here is the case for physician supervision, and it does not rest on any efficacy claim.

• Diagnosis before prescription. Both the Endocrine Society and the AUA require two separate early-morning measurements, because a single draw misclassifies roughly one man in three. Add LH and FSH to separate a testicular cause from a pituitary one, and screen the mimics — thyroid, iron, sleep apnea, medications.
• Red cell mass. Testosterone raises hematocrit, and it does so far more with injections than with gels. In one large randomized trial of injectable testosterone, 22 percent of men crossed a hematocrit of 54 percent, against 1 percent on placebo. It is invisible without a blood count, it is entirely predictable, and it has a straightforward answer — dose adjustment, a change of route, or donation — provided someone is looking.
• Blood pressure. The same 2025 FDA action that removed the cardiovascular boxed warning added a warning about blood pressure across the class. It belongs on the monitoring list, at every visit.
• Prostate and estradiol. PSA before and during. Estradiol measured on a sensitive assay when symptoms warrant it, because the standard immunoassay is unreliable in men.
• Fractures and falls. Given the TRAVERSE finding, therapy runs alongside resistance training, vitamin D and attention to balance — not as a substitute for them.

None of this is exotic. It is a panel, an interval, and someone whose job it is to read them. It is also the entire difference between the man who feels transformed at six months and the man who feels jittery, quits at three, and concludes the whole category is a scam.

The conversation to have before you start

Testosterone from outside the body suppresses the pituitary signals that drive your own production — including sperm production. Suppression to azoospermia is common on full replacement doses. Recovery, in the largest pooled analysis available, has a median of about 3.4 months, with roughly ninety percent of men back to threshold within a year and essentially all within two. Those are reassuring numbers, but they are numbers a man should hear before starting rather than after.

If your family is not finished, there are good routes: bank sperm first; run hCG alongside therapy to keep your own production going; or use a restart protocol later. Worth knowing that hCG is FDA-approved for hypogonadotropic hypogonadism in males, that clomiphene in men is off-label, and that enclomiphene has never been FDA-approved for any indication and exists only as a compounded preparation. We will tell you which is which.

One more, briefly: testosterone is prohibited at all times under the WADA code. If you compete in any tested sport, including masters events, this is a conversation to have on day one.

Where that leaves you

The cardiovascular question that scared men off for a decade has been answered as well as a 5,000-man randomized trial can answer it. The regulatory language has followed. What remains is the part that was always the real work: establishing whether you are actually deficient, finding out why, deciding with a physician whether treatment is the right answer, and then watching the handful of things that genuinely need watching.

That is not a prescription you can order online, and it is not a number on a menu. You can read how we handle testosterone therapy, or look at what a full baseline panel covers.

Written by Athlos Health, Torrance, California. This article is general education and is not medical advice, a diagnosis, or a treatment recommendation. Testosterone is a Schedule III controlled substance and is prescribed only after individual evaluation by a physician. The full risk discussion happens in consultation and in writing before anything is prescribed. Every figure above is linked to its source below.